Naila Rabbani is the head of proteomics at the QU Health cluster at Qatar University. She is a leading glycation researcher, developed the AGEomics technology, and is an expert in the development of diagnostic algorithms. She has over 147 publications and 9 patents, receiving over 15,000 citations and an h-index of 67. She is pursuing research on glyoxalase 1 inducers for the prevention, reversal, and treatment of type 2 diabetes, chronic vascular complications of diabetes, biomarkers for the risk prediction of diabetic vascular complications, arthritis, and autism. Recently, she is also studying the application of glyoxalase research to the treatment of COVID-19.